Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Aggression × vandetanib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 22 Carcinoma, Medullary 14 Neoplasm Metastasis 12 Lung Neoplasms 12 Thyroid Neoplasms 8 Neoplasms 7 Breast Neoplasms 7 Glioma 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Gliosarcoma 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Thyroid Cancer, Papillary 2 Recurrence 2 Kidney Neoplasms 2 Familial medullary thyroid carcinoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Disease Progression 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Biliary Tract Neoplasms 2 Adenocarcinoma, Follicular 2

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 glofitamab 1 Topotecan 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Clofarabine 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01945762 2024-12-18

Caprelsa104

Sanofi

Aggression, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡